Brazil’s Multidrug-Resistant Tuberculosis Burden Climbing Across High-Risk Groups

Multidrug-resistant tuberculosis is no longer confined to isolated clinical settings or a narrow slice of the population. In Brazil, notifications rose across every high-risk group examined from 2001 through 2021, with the most abrupt acceleration appearing between 2017 and 2021. The pattern is clinically familiar and epidemiologically alarming: once MDR-TB becomes entrenched in vulnerable communities, delayed diagnosis, inconsistent treatment, and sustained transmission begin to reinforce one another.

The analysis used DATASUS notification data and organized cases by time period and by risk strata that included people living with HIV, smokers, drug users, healthcare workers, incarcerated individuals, and people experiencing homelessness. Across those strata, growth in cases ranged from 294% to 574% in the final interval examined. Even without individual-level linkage, the direction of travel is unmistakable. The burden did not stay static in any group, and the steepest increases arrived late in the study window rather than earlier, when public health systems may have had more room to interrupt transmission.

Why the Increase Concentrated in Vulnerable Populations

The epidemiology of MDR-TB is inseparable from treatment failure and social exposure. When standard tuberculosis therapy is interrupted or abandoned, resistant organisms have a survival advantage and can seed future cases. That biological mechanism is especially consequential in settings where coinfection, unstable housing, incarceration, substance use, and occupational exposure cluster in the same communities. In practice, those conditions do not act independently; they compound one another and increase the probability that an initially susceptible infection becomes difficult to cure and easier to transmit.

HIV-positive individuals represent one of the clearest examples of this convergence. Immunosuppression raises the risk of active tuberculosis, while diagnostic delay and competing clinical priorities can complicate treatment adherence. Among smokers and drug users, the issue is not merely exposure but also the structural barriers that interfere with early evaluation, consistent follow-up, and completion of therapy. Incarcerated populations face dense contact networks and delayed access to diagnostic services, while people experiencing homelessness often encounter fragmented care long before resistance is documented. Healthcare workers sit in a different category, but occupational exposure keeps them inside the transmission chain when infection control is imperfect.

A 574% rise in one of these strata is not a statistical curiosity. It signals a system under strain.

The Late Surge Suggests Persistent Gaps in Detection and Follow-Up

The sharpest increase between 2017 and 2021 deserves particular attention because it suggests that prior control measures did not meaningfully contain the reservoir of resistant disease. If surveillance improves while incidence remains flat, one might expect a modest rise in notifications without a parallel epidemiologic expansion. Here, the increase was substantial across all groups, which argues for a true worsening of the underlying problem rather than a reporting artifact alone. The timing also fits a scenario in which incomplete treatment, ongoing transmission in congregate settings, and persistent barriers to care gradually accumulated until they became visible in national notification data.

Statistical testing with ANOVA and Tukey methods supported differences across periods, using a significance threshold of p less than 0.05. The investigators did not present a randomized comparison or a treatment trial; this was a cross-sectional epidemiological study built on routine surveillance. Even so, the findings carry weight because they describe the practical endpoint that public health systems must confront: increasing counts of resistant disease in people already at elevated risk for poor outcomes.

Public Health Practice Has to Move Beyond Passive Surveillance

Brazil’s MDR-TB burden among high-risk populations will not fall through passive reporting alone. Notification systems can identify the shape of the epidemic, but they do not cure patients, prevent treatment abandonment, or reduce transmission in the settings where risk concentrates. The study points toward a more aggressive response built around early case finding, uninterrupted drug support, and closer therapeutic follow-up for groups most likely to fall out of care. In communities facing homelessness, incarceration, substance use, or HIV coinfection, tuberculosis control must be integrated with social and primary care services rather than delivered as a separate, episodic intervention.

For healthcare workers, prevention depends on early recognition, fit-for-purpose infection control, and rapid access to diagnostic confirmation when exposure occurs. For incarcerated populations, congregate transmission demands system-level screening and continuity of treatment during transfers and release. For people with substance use disorders, adherence support has to account for instability, competing priorities, and the practical barriers that make long-course therapy hard to complete. Those same forces likely help explain why resistant disease persists after the first wave of diagnosis has passed.

What This Preprint Can and Cannot Prove

As a preprint, the analysis remains outside peer review, and its conclusions should be interpreted with that context in mind. Routine surveillance data also have inherent limits: they cannot fully capture individual adherence, microbiologic confirmation practices, treatment history, or the many local factors that shape resistance. The study identifies rising notifications, not the full causal chain behind each case. Still, the broad signal is robust enough to matter. When MDR-TB rates rise across every high-risk group studied, especially over a short recent interval, the problem is not confined to one demographic or one region of care.

Brazil’s public health response now faces a concrete challenge: interrupt the pathways that allow resistant tuberculosis to spread through the populations least able to absorb another treatment failure. Without earlier diagnosis, stronger retention in care, and better protection in high-exposure settings, the notification curve is likely to keep climbing.


Reporting by Dr. A.R. Athira, MBBS for Medicine World Foundation, with additional data provided by medRxiv (Clinical Preprints).
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA